SPATIAL TRANSCRIPTOMICS IDENTIFIES IL-32 AS A LIPID DROPLET-ASSOCIATED CYTOKINE LINKED TO TUBULAR INJURY IN HUMAN DIABETIC KIDNEY DISEASE

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/0b0905e7a627a917e5131ba716f1dfe2.pdf

Abstract Title *

SPATIAL TRANSCRIPTOMICS IDENTIFIES IL-32 AS A LIPID DROPLET-ASSOCIATED CYTOKINE LINKED TO TUBULAR INJURY IN HUMAN DIABETIC KIDNEY DISEASE

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Kieran Meadows kieran.meadows1@ucalgary.ca University of Calgary Medicine Calgary Canada *

Co-author 2

Hyunjae Chung hjchun@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 3

Son Vo sonvo@bioturing.com BioTuring BioTuring San Diego United States -

Co-author 4

Aysa Imanzadeh aysa.imanzadeh1@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 5

Heewon Seo heewon.seo@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 6

Sisay Belay sisay.belay@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 7

Asha Swamy aswam093@uottawa.ca University of Calgary Medicine Calgary Canada -

Co-author 8

Wulin Teo wteo@ucalgary.ca University of Calgary Clinical Neurosciences Calgary Canada -

Co-author 9

Kevin Chapman kchapman@ucalgary.ca University of Calgary Pathology and Laboratory Medicine Calgary Canada -

Co-author 10

Graciela Andonegui andonegu@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 11

Hallgrimur Benediktsson benedikt@ucalgary.ca University of Calgary Pathology and Laboratory Medicine Calgary Canada -

Co-author 12

Peter Stys pstys@ucalgary.ca University of Calgary Clinical Neurosciences Calgary Canada -

Co-author 13

Thang Pham thang@bioturing.com BioTuring BioTuring San Diego United States -

Co-author 14

Daniel Muruve dmuruve@ucalgary.ca University of Calgary Medicine Calgary Canada -

Co-author 15